(19)
(11) EP 2 791 673 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
13.03.2019 Bulletin 2019/11

(45) Mention of the grant of the patent:
29.08.2018 Bulletin 2018/35

(21) Application number: 12858515.5

(22) Date of filing: 14.12.2012
(51) International Patent Classification (IPC): 
G01N 33/48(2006.01)
G01N 33/53(2006.01)
G01N 33/483(2006.01)
G01N 33/68(2006.01)
(86) International application number:
PCT/CA2012/050900
(87) International publication number:
WO 2013/086637 (20.06.2013 Gazette 2013/25)

(54)

LAMIN A/C AND PRELAMINS AS INDICATORS OF FRAILTY AND VULNERABILITY OR RESILIENCY TO ADVERSE HEALTH OUTCOMES

LAMIN A/C UND PRÄLAMINE ALS INDIKATOREN VON Gebrechlichkeit UND VERWUNDBARKEIT ODER Belastbarkeit FÜR GESUNDHEITSSCHÄDIGENDE ERGEBNISSE

LAMINE A/C ET PRÉLAMINES CONVENANT COMME INDICATEURS DE FRAGILITÉ ET DE VULNÉRABILITÉ OU DE RÉSILIENCE FACE À DES RÉSULTATS CLINIQUES DÉFAVORABLES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.12.2011 US 201161576628 P

(43) Date of publication of application:
22.10.2014 Bulletin 2014/43

(73) Proprietors:
  • Afilalo, Jonathan
    Cote St Luc QC H3X 4B3 (CA)
  • Ohayon, Samuel Meyer
    Montreal QC H2J 3N1 (CA)
  • Afilalo, Marc
    Cote St Luc QC H4V 1C2 (CA)

(72) Inventors:
  • Afilalo, Jonathan
    Cote St Luc QC H3X 4B3 (CA)
  • Ohayon, Samuel Meyer
    Montreal QC H2J 3N1 (CA)
  • Afilalo, Marc
    Cote St Luc QC H4V 1C2 (CA)

(74) Representative: Cabinet Plasseraud 
66, rue de la Chaussée d'Antin
75440 Paris Cedex 09
75440 Paris Cedex 09 (FR)


(56) References cited: : 
US-A1- 2010 297 618
   
  • AFILALO J ET AL: "Gait Speed as an Incremental Predictor of Mortality and Major Morbidity in Elderly Patients Undergoing Cardiac Surgery", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 56, no. 20, 9 November 2010 (2010-11-09), pages 1668-1676, XP027459594, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2010.06.039 [retrieved on 2010-11-02]
  • Jonathan Afilalo: "Frailty Assessment Before Cardiac Surgery Thesis candidate", , 1 January 2011 (2011-01-01), XP055187864, Retrieved from the Internet: URL:http://digitool.library.mcgill.ca/thes isfile92222.pdf [retrieved on 2015-05-06]
  • WU ET AL.: 'Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma' JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH vol. 28, no. 8, 15 January 2009, pages 1 - 12, XP021053022
  • MOSS ET AL.: 'Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms' GUT vol. 45, 1999, pages 723 - 729, XP002459319
  • TANG ET AL.: 'Promotion of tmnor development in prostate cancer bv progerin' CANCER CELL INTERNATIONAL vol. 10, no. 47, 2010, pages 1 - 10, XP021088181
  • TONG ET AL.: 'Lamin A/C deficiencv is associated with fat infiltration of muscle and bone' MECHANISMS OF AGEING AND DEVELOPMENT vol. 132, 01 October 2011, pages 552 - 559, XP055073160
  • AFILALO, J.: 'Frailty in Patients with Cardiovascular Disease: Why, When and How to Measure' CURR. CARDIOVASC. RISK. REP. vol. 5, 02 August 2011, pages 467 - 472, XP019947127
  • WILLIS ET AL.: 'Lamin A/C Is a Risk Biomarker in Colorectal Cancer' PLOS ONE vol. 3, no. 8, 20 August 2008, page E2988, XP055073161
  • LI ET AL.: 'Decreased Bone Formation and Osteopenia in Lamin A/C- Deficient Mice, e19313' PLOS ONE vol. 6, no. 4, 25 April 2011, XP055073162
  • AFILALO ET AL.: 'Age-related changes in lamin A/C expression in cardiomyocytes' AMERICAN JOURNAL OF PHYSIOLOGY - HEAT AND CIRCULATORY PHYSIOLOGY vol. 293, 18 May 2007, pages H1451 - H1456, XP055073164
  • MALHOTRA ET AL.: 'Lamin A/C deficiency as a cause of familial dilated cardiomyopathy' CURRENT OPINION IN CARDIOLOGY vol. 24, 2009, pages 203 - 208, XP008174631
  • HUDSON ET AL.: 'Identification of differentiallv expressed proteins in ovarian cancer using high-density-protein microarravs' PNAS vol. 104, no. 44, 30 October 2007, pages 17494 - 17499, XP055024503
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).